EMA Reorganizes

Article

EMA restructures organization.

The European Medicines Agency is moving forward with plans to restructure the organization. EMA’s management team began transitioning to a new structure on August 1, 2013.

The Agency expects to complete the full transition period for the new structure and the revised operating processes in 2014.  In the meantime, it will ensure continuity of operations for the evaluation and supervision of medicines.

The agency is creating four new divisions that will support and focus on research and development; evaluate lifecycle management; develop procedures for management and business data; and inspections and pharmacovigilance.

EMA will announce details of the new structure of the organization in September 2013.

Source:

European Medicines Agency


Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content